-
Je něco špatně v tomto záznamu ?
Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy
C. Catalano, MI. da Silva Filho, K. Jiraskova, V. Vymetalkova, M. Levy, V. Liska, O. Vycital, A. Naccarati, L. Vodickova, K. Hemminki, P. Vodicka, ANR. Weber, A. Försti,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- časové faktory MeSH
- dospělí MeSH
- fenotyp MeSH
- fluoruracil aplikace a dávkování škodlivé účinky MeSH
- frekvence genu MeSH
- genetická predispozice k nemoci MeSH
- genetické asociační studie MeSH
- intracelulární signální peptidy a proteiny genetika MeSH
- jednonukleotidový polymorfismus * MeSH
- Kaplanův-Meierův odhad MeSH
- kolorektální nádory farmakoterapie genetika mortalita patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery genetika MeSH
- přežití bez známek nemoci MeSH
- proporcionální rizikové modely MeSH
- protokoly protinádorové kombinované chemoterapie škodlivé účinky terapeutické užití MeSH
- rizikové faktory MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- studie případů a kontrol MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
BACKGROUND: NLRC5 is an interferon γ-inducible protein, which plays a role in immune surveillance with a potential influence on cancer survival. OBJECTIVE: We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients. PATIENTS AND METHODS: We carried out a case-only study in a Czech population of 589 cases; 232 received 5-FU-based therapy. Eleven variants within NLRC5 were selected using in-silico tools. Associations between polymorphisms and survival were assessed by Cox regression analysis adjusting for age at diagnosis, sex, and TNM stage. Survival curves were derived using the Kaplan-Meier method. RESULTS: Two variants showed a significant association with survival. All patients and metastasis-free patients at the time of diagnosis (pM0) who were homozygous carriers of the minor allele of rs27194 had a decreased overall survival (OSall and OSpM0) and event-free survival (EFSpM0) under a recessive model (OSall P=0.003, OSpM0 P=0.005, EFSpM0 P=0.01, respectively). OS was also decreased for all patients and for pM0 patients who carried at least one minor allele of rs289747 (OSall P=0.03 and OSpM0 P=0.003, respectively). Among CRC patients, who underwent a 5-FU-based adjuvant regimen, rs12445252 was associated with OSall, OSpM0 and EFSpM0, according to the dosage of the minor allele T (OSall P=0.0004, OSpM0 P=0.0001, EFSpM0 P=0.008, respectively). CONCLUSION: Our results showed that polymorphisms in NLRC5 may be used as prognostic markers of survival of CRC patients, as well as for survival in response to 5-FU treatment.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000735
- 003
- CZ-PrNML
- 005
- 20190118111653.0
- 007
- ta
- 008
- 190107s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MEG.0000000000001154 $2 doi
- 035 __
- $a (PubMed)29762254
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Catalano, Calogerina $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg.
- 245 10
- $a Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy / $c C. Catalano, MI. da Silva Filho, K. Jiraskova, V. Vymetalkova, M. Levy, V. Liska, O. Vycital, A. Naccarati, L. Vodickova, K. Hemminki, P. Vodicka, ANR. Weber, A. Försti,
- 520 9_
- $a BACKGROUND: NLRC5 is an interferon γ-inducible protein, which plays a role in immune surveillance with a potential influence on cancer survival. OBJECTIVE: We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients. PATIENTS AND METHODS: We carried out a case-only study in a Czech population of 589 cases; 232 received 5-FU-based therapy. Eleven variants within NLRC5 were selected using in-silico tools. Associations between polymorphisms and survival were assessed by Cox regression analysis adjusting for age at diagnosis, sex, and TNM stage. Survival curves were derived using the Kaplan-Meier method. RESULTS: Two variants showed a significant association with survival. All patients and metastasis-free patients at the time of diagnosis (pM0) who were homozygous carriers of the minor allele of rs27194 had a decreased overall survival (OSall and OSpM0) and event-free survival (EFSpM0) under a recessive model (OSall P=0.003, OSpM0 P=0.005, EFSpM0 P=0.01, respectively). OS was also decreased for all patients and for pM0 patients who carried at least one minor allele of rs289747 (OSall P=0.03 and OSpM0 P=0.003, respectively). Among CRC patients, who underwent a 5-FU-based adjuvant regimen, rs12445252 was associated with OSall, OSpM0 and EFSpM0, according to the dosage of the minor allele T (OSall P=0.0004, OSpM0 P=0.0001, EFSpM0 P=0.008, respectively). CONCLUSION: Our results showed that polymorphisms in NLRC5 may be used as prognostic markers of survival of CRC patients, as well as for survival in response to 5-FU treatment.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a kolorektální nádory $x farmakoterapie $x genetika $x mortalita $x patologie $7 D015179
- 650 _2
- $a Česká republika $7 D018153
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fluoruracil $x aplikace a dávkování $x škodlivé účinky $7 D005472
- 650 _2
- $a frekvence genu $7 D005787
- 650 _2
- $a genetické asociační studie $7 D056726
- 650 _2
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a intracelulární signální peptidy a proteiny $x genetika $7 D047908
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a fenotyp $7 D010641
- 650 12
- $a jednonukleotidový polymorfismus $7 D020641
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a da Silva Filho, Miguel I $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg.
- 700 1_
- $a Jiraskova, Katerina $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences. Institute of Biology and Medical Genetics, First Faculty of Medicine.
- 700 1_
- $a Vymetalkova, Veronika $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences. Institute of Biology and Medical Genetics, First Faculty of Medicine.
- 700 1_
- $a Levy, Miroslav $u Department of Surgery, First Medical Faculty, Charles University and Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a Liska, Vaclav $u Biomedical Centre, Faculty of Medicine, Pilsen. Department of Surgery, First Medical Faculty, Charles University and Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a Vycital, Ondrej $u Biomedical Centre, Faculty of Medicine, Pilsen. Department of Surgery, First Medical Faculty, Charles University and Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a Naccarati, Alessio $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences. Molecular and Genetic Epidemiology, Italian Institute for Genomic Medicine (IIGM), Turin, Italy.
- 700 1_
- $a Vodickova, Ludmila $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences. Institute of Biology and Medical Genetics, First Faculty of Medicine. Biomedical Centre, Faculty of Medicine, Pilsen.
- 700 1_
- $a Hemminki, Kari $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg. Center for Primary Health Care Research, Clinical Research Center, Lund University, Malmö, Sweden.
- 700 1_
- $a Vodicka, Pavel $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences. Institute of Biology and Medical Genetics, First Faculty of Medicine. Biomedical Centre, Faculty of Medicine, Pilsen.
- 700 1_
- $a Weber, Alexander N R $u Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
- 700 1_
- $a Försti, Asta $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg. Center for Primary Health Care Research, Clinical Research Center, Lund University, Malmö, Sweden.
- 773 0_
- $w MED00001618 $t European journal of gastroenterology & hepatology $x 1473-5687 $g Roč. 30, č. 8 (2018), s. 838-842
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29762254 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190118111908 $b ABA008
- 999 __
- $a ok $b bmc $g 1364751 $s 1038858
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 30 $c 8 $d 838-842 $i 1473-5687 $m European journal of gastroenterology & hepatology $n Eur J Gastroenterol Hepatol $x MED00001618
- LZP __
- $a Pubmed-20190107
